

Ruby Yun-Ju Huang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/658514/ruby-yun-ju-huang-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80
papers

13,408
citations

33
h-index

95
g-index

95
ext. papers

15,919
ext. citations

8.2
avg, IF

6.78
L-index

#	Paper	IF	Citations
80	Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach.. <i>Frontiers in Oncology</i> , 2021 , 11, 783803	5.3	0
79	Evolution of CP2 transcription factors in Hexapoda. <i>Journal of Genetics</i> , 2021 , 100, 1	1.2	0
78	Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies. <i>Cells Tissues Organs</i> , 2021 , 1-16	2.1	11
77	A reasoned approach towards administering COVID-19 vaccines to pregnant women. <i>Prenatal Diagnosis</i> , 2021 , 41, 1018-1035	3.2	3
76	Putting the BRK on breast cancer: From molecular target to therapeutics. <i>Theranostics</i> , 2021 , 11, 1115-1128	11.2	5
75	High-throughput functional profiling of single adherent cells hydrogel drop-screen. <i>Lab on A Chip</i> , 2021 , 21, 764-774	7.2	3
74	Prognostic significance of phosphoglycerate dehydrogenase in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 186, 655-665	4.4	0
73	High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia. <i>Npj Breast Cancer</i> , 2021 , 7, 88	7.8	1
72	Epigenetic derepression converts PPAR α into a druggable target in triple-negative and endocrine-resistant breast cancers. <i>Cell Death Discovery</i> , 2021 , 7, 265	6.9	1
71	SNAI1-Driven Sequential EMT Changes Attributed by Selective Chromatin Enrichment of RAD21 and GRHL2. <i>Cancers</i> , 2020 , 12,	6.6	4
70	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020 , 26, 5411-5423	12.9	21
69	Inflammatory and mitogenic signals drive interleukin 23 subunit alpha (IL23A) secretion independent of IL12B in intestinal epithelial cells. <i>Journal of Biological Chemistry</i> , 2020 , 295, 6387-6400	5.4	9
68	Functional reservoir microcapsules generated via microfluidic fabrication for long-term cardiovascular therapeutics. <i>Lab on A Chip</i> , 2020 , 20, 2756-2764	7.2	13
67	Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective. <i>Cancers</i> , 2020 , 12,	6.6	32
66	Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma Oxidative Stress and Iron-Sulfur Cluster Biogenesis Deficit. <i>Antioxidants and Redox Signaling</i> , 2020 , 33, 1191-1208	8.4	8
65	Effect of inhibition of receptor tyrosine kinase AXL by a selective small molecular inhibitor R428 (BGB321) on DNA damage repair response in ovarian cancer cells.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15640-e15640	2.2	
64	Stopping transformed cancer cell growth by rigidity sensing. <i>Nature Materials</i> , 2020 , 19, 239-250	27	45

63	Two high-yield complementary methods to sort cell populations by their 2D or 3D migration speed. <i>Molecular Biology of the Cell</i> , 2020 , 31, 2779-2790	3.5	
62	Pharmacological Inhibition of BAD Ser99 Phosphorylation Enhances the Efficacy of Cisplatin in Ovarian Cancer by Inhibition of Cancer Stem Cell-like Behavior. <i>ACS Pharmacology and Translational Science</i> , 2020 , 3, 1083-1099	5.9	3
61	Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma. <i>Scientific Reports</i> , 2020 , 10, 18503	4.9	1
60	Spotlight on the Granules (Grainyhead-Like Proteins) - From an Evolutionary Conserved Controller of Epithelial Trait to Pioneering the Chromatin Landscape. <i>Frontiers in Molecular Biosciences</i> , 2020 , 7, 213	5.6	6
59	RNA-Binding Protein Suppresses Hypoxia and Cell-Cycle Signaling. <i>Cancer Research</i> , 2020 , 80, 219-233	10.1	16
58	SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition. <i>Scientific Reports</i> , 2019 , 9, 8295	4.9	15
57	Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention. <i>Physical Biology</i> , 2019 , 16, 041004	3	33
56	The role of GRHL2 and epigenetic remodeling in epithelial-mesenchymal plasticity in ovarian cancer cells. <i>Communications Biology</i> , 2019 , 2, 272	6.7	30
55	Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity. <i>Cancers</i> , 2019 , 12,	6.6	28
54	Actin cytoskeleton self-organization in single epithelial cells and fibroblasts under isotropic confinement. <i>Journal of Cell Science</i> , 2019 , 132,	5.3	30
53	Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. <i>EBioMedicine</i> , 2019 , 50, 203-210	8.8	25
52	Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. <i>European Urology</i> , 2019 , 75, 423-432	10.2	120
51	The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma. <i>Molecular Oncology</i> , 2019 , 13, 757-780	7.9	11
50	Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer. <i>Journal of Pathology</i> , 2019 , 247, 305-319	9.4	9
49	Reply to Pontus Eriksson and Gottfrid Sjöbahl Letter to the Editor re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. <i>Eur Urol</i> 2019;75:423-32. <i>European Urology</i> , 2019 , 75, e108-e109	10.2	4
48	Dual role of autophagy in hallmarks of cancer. <i>Oncogene</i> , 2018 , 37, 1142-1158	9.2	288
47	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. <i>EMBO Reports</i> , 2018 , 19,	6.5	20
46	Thymoquinone Inhibits Bone Metastasis of Breast Cancer Cells Through Abrogation of the CXCR4 Signaling Axis. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1294	5.6	90

45	The EMT spectrum and therapeutic opportunities. <i>Molecular Oncology</i> , 2017 , 11, 878-891	7.9	59
44	Targeting the AXL signaling pathway in ovarian cancer. <i>Molecular and Cellular Oncology</i> , 2017 , 4, e1263716		8
43	Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer. <i>Gene</i> , 2017 , 635, 9-15	3.8	17
42	LncTing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling. <i>British Journal of Pharmacology</i> , 2017 , 174, 4684-4700	8.6	47
41	AXL-Driven EMT State as a Targetable Conduit in Cancer. <i>Cancer Research</i> , 2017 , 77, 3725-3732	10.1	85
40	Intracellular Hyper-Acidification Potentiated by Hydrogen Sulfide Mediates Invasive and Therapy Resistant Cancer Cell Death. <i>Frontiers in Pharmacology</i> , 2017 , 8, 763	5.6	16
39	Hypoxia-inducible factor-1 α promotes cell survival during ammonia stress response in ovarian cancer stem-like cells. <i>Oncotarget</i> , 2017 , 8, 114481-114494	3.3	23
38	A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. <i>Cancer Letters</i> , 2016 , 382, 203-214	9.9	64
37	A new dimension in drug discovery: reversing epithelial-mesenchymal transition (EMT). <i>Cell Death and Disease</i> , 2016 , 7, e2417	9.8	4
36	The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. <i>Science Signaling</i> , 2016 , 9, ra97	8.8	76
35	GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. <i>Scientific Reports</i> , 2016 , 6, 19943	4.9	88
34	Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2016 , 5, e1191731	7.2	122
33	Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e17084-e17084	2.2	
32	EMT: 2016. <i>Cell</i> , 2016 , 166, 21-45	56.2	2443
31	LNK (SH2B3): paradoxical effects in ovarian cancer. <i>Oncogene</i> , 2015 , 34, 1463-74	9.2	17
30	The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. <i>Human Pathology</i> , 2015 , 46, 1-8	3.7	42
29	CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. <i>Oncotarget</i> , 2015 , 6, 43843-52	3.3	46
28	Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120). <i>Oncotarget</i> , 2015 , 6, 22098-1133	3.3	36

27	Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. <i>EMBO Molecular Medicine</i> , 2014 , 6, 1279-93	12	399
26	A spatiotemporally defined in vitro microenvironment for controllable signal delivery and drug screening. <i>Analyst, The</i> , 2014 , 139, 4846-54	5	17
25	Modeling of cancer metastasis and drug resistance via biomimetic nano-cilia and microfluidics. <i>Biomaterials</i> , 2014 , 35, 1562-71	15.6	53
24	Lgr5 marks stem/progenitor cells in ovary and tubal epithelia. <i>Nature Cell Biology</i> , 2014 , 16, 745-57	23.4	153
23	FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. <i>Cell Death and Disease</i> , 2014 , 5, e1346	9.8	77
22	Drug Screening: Rapid Prototyping of Concave Microwells for the Formation of 3D Multicellular Cancer Aggregates for Drug Screening (Adv. Healthcare Mater. 4/2014). <i>Advanced Healthcare Materials</i> , 2014 , 3, 620-620	10.1	
21	Rapid prototyping of concave microwells for the formation of 3D multicellular cancer aggregates for drug screening. <i>Advanced Healthcare Materials</i> , 2014 , 3, 609-16	10.1	58
20	Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. <i>Integrative Biology (United Kingdom)</i> , 2013 , 5, 381-9	3.7	123
19	An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). <i>Cell Death and Disease</i> , 2013 , 4, e915	9.8	269
18	Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. <i>EMBO Molecular Medicine</i> , 2013 , 5, 1051-66	12	178
17	Early events in cell adhesion and polarity during epithelial-mesenchymal transition. <i>Journal of Cell Science</i> , 2012 , 125, 4417-22	5.3	222
16	Histotype-specific copy-number alterations in ovarian cancer. <i>BMC Medical Genomics</i> , 2012 , 5, 47	3.7	35
15	Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis. <i>Journal of Translational Medicine</i> , 2012 , 10, 121	8.5	20
14	Lysophosphatidic acid modulates the association of PTP1B with N-cadherin/catenin complex in SKOV3 ovarian cancer cells. <i>Cell Biology International</i> , 2012 , 36, 833-41	4.5	7
13	Configurable 2D and 3D spheroid tissue cultures on bioengineered surfaces with acquisition of epithelial-mesenchymal transition characteristics. <i>NPG Asia Materials</i> , 2012 , 4, e27-e27	10.3	32
12	Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. <i>Current Drug Targets</i> , 2012 , 13, 1649-53	3	63
11	Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept. <i>Advanced Drug Delivery Reviews</i> , 2011 , 63, 558-67	18.5	36
10	Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. <i>PLoS ONE</i> , 2011 , 6, e28561	3.7	38

9	Epithelial-mesenchymal transitions in development and disease. <i>Cell</i> , 2009 , 139, 871-90	56.2	7255
8	Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120-catenin. <i>International Journal of Cancer</i> , 2008 , 123, 801-9	7.5	23
7	Linking epithelial-mesenchymal transition to the well-known polarity protein Par6. <i>Developmental Cell</i> , 2005 , 8, 456-8	10.2	28
6	Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. <i>Carcinogenesis</i> , 2005 , 26, 45-52	4.6	70
5	Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB. <i>Oncogene</i> , 2005 , 24, 390-8	9.2	57
4	Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. <i>Gynecologic Oncology</i> , 2004 , 94, 197-203	4.9	81
3	Clinical Presentation of Pelvic Tuberculosis Imitating Ovarian Malignancy. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2004 , 43, 29-34	1.6	6
2	Actin cytoskeleton self-organization in single epithelial cells and fibroblasts under isotropic confinement		1
1	Case study: Digital spatial profiling of metastatic clear cell carcinoma reveals intra-tumor heterogeneity in epithelial-mesenchymal gradient		